Skip to main content

Table 5 HZ as co-morbidity analyses: LOS, death rate and economic evaluation

From: Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France

   Circulatory system Respiratory system Osteoarticulary system Digestive system Diabetes
LOS
       Median (days) Casesa 11 12 9 8 9
  Controlb 5 7 6 2 5
       Median difference days 6 5 3 6 4
       % rise 1.2 % 0.71 % 0.5 % 3 % 0.8 %
       Tests (Wilcoxon-Mann–Whitney) (p values 0,05) <0.0100 <0.0001 <0.0001 <0.0001 <0.0001
Death rate
       Deaths among cases cohorta      
  Death rate (%) 32/615 41/481 5/268 16/275 1/78
       Deaths among control cohortb 5.2 % 8.52 % 1.86 % 5.81 % 1.28 %
  Death rate (%) 113/1,845 155/1,443 2/804 26/825 3/234
       Chi-square probability (p value 0,05) 6.12 % 10.74 % 0.24 % 3.15 % 1.28 %
Hospital stay cost
       Median (€) Cases cohorta 4,228 4,534 4,475 3,601 3,510
  Control cohortb 3,371 3,589 3,553 1,590 2,523
       Median difference (€) 857 945 922 2,011 987
       % rise 25 % 26 % 26 % 126 % 39 %
       Tests (Wilcoxon-Mann–Whitney) (p value 0,05) <0.0100 <0.0001 <0.0001 <0.0001 <0.0001
  1. HZ: Herpes Zoster
  2. LOS: Length of stay
  3. aCohort of patients hospitalized with HZ in SAD
  4. bCohort of patients hospitalized without HZ in SAD